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Novel palliative strategies for patients with androgen-independent prostate cancer (AIPC) include targeting the epidermal growth
factor receptor (EGFR) family. The aim of the present study was to investigate intrapatient changes of EGFRs during the development
of AIPC. In total, 106 symptomatic AIPC patients were identified in whom prostatic biopsies (adenocarcinoma) were available both
before the start of androgen deprivation (PRTR biopsy) and after the development of AIPC (AIPC biopsy). All four known subgroups
of the EGFR family were determined by immunohistochemistry (IHC): c-erbB-1 (EGFR), c-erbB-2 (HER2/neu), c-erbB-3 (HER3) and
c-erbB-4 (HER4). Moderate to strong membrane-specific staining was recorded semiquantitatively (o10% vs X10%¼IHC stained
tumour cells: ‘negative’ vs ‘positive’ staining). The medical records were reviewed for clinical variables. During the development of
AIPC, intrapatient changes occurred in two opposite directions for each of the four EGFRs: negativity changed to positivity, and vice
versa, statistically significant only for the increase of c-erbB-1 expression (P¼0.001). The c-erbB-2 expression in the AIPC biopsy was
associated with a significantly shorter survival from the time of the AIPC biopsy (P¼0.029). Our results support ongoing therapeutic
attempts of EGFR inhibition in subgroups of patients with prostate cancer. Further research is needed to understand the function of
EGFRs in this malignancy.
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Androgen-independent prostate cancer (AIPC) is defined as
biochemical and/or clinical disease progression during androgen
deprivation with castration levels of serum testosterone. Patients
are in need of palliation, and novel strategies focus on the
epidermal growth factor receptor (EGFR) family and related
intracellular pathways.
Based on current knowledge, the EGFR family comprises four
members; c-erbB-1 (EGFR), c-erbB-2 (HER2/neu), c-erbB-3
(HER3) and c-erbB-4 (HER4) (Olayioye et al, 2000;Suo and
Nesland, 2002). All members of this family have an extracellular
ligand-binding domain, a single transmembrane domain and a
cytoplasmatic tyrosine kinase domain, which for c-erbB-3 is
nonfunctioning. Binding of ligands to the extracellular domains
leads to the formation of homo- and heterodimers. This starts a
complex signalling cascade finally resulting in cellular prolifera-
tion, prevention of apoptosis and promotion of tumour cell
mobility, adhesion and invasion (Barton et al, 2001).
Previous observations have demonstrated increased levels of
c-erbB-1 immunoreactivity in hormone-independent human
prostate cancer cell lines (MacDonald and Habib, 1992; Sherwood
et al, 1998). In tissue from patients with metastatic AIPC, the
c-erbB-1 expression has been reported as high as about 90–100%
(Scher et al, 1995; Di Lorenzo et al, 2002). For c-erbB-2 expression,
there have been reports of divergent rates in primary prostate
carcinoma (Mellon et al, 1992; Kuhn et al, 1993; Fossa et al, 2002).
In xenografts, an upregulation of c-erbB-2 has been found when
the tumour becomes androgen-independent (Craft et al, 1999). In
tumours from patients with AIPC, c-erbB-2 expression is reported
from relatively uncommon (Reese, 2001; Savinainen et al, 2002) up
to about 50–80% (Signoretti et al, 2000; Osman et al, 2001; Di
Lorenzo et al, 2002).
To the best of our knowledge, data are lacking from a larger
series that compare the expression of all EGFRs for the same
patient before and after the development of AIPC. The primary
aim of the present study is to fill this gap and, secondarily, to
provide information about the prognostic significance of EGFR
expression in AIPC patients.
MATERIALS AND METHODS
From the files of the Department of Pathology, The Norwegian
Radium Hospital (NRH), we identified AIPC patients with an
adenocarcinoma-positive biopsy from the prostate before the
start of androgen deprivation (pretreatment (PRTR) biopsy) and
after the development of symptomatic AIPC (AIPC biopsy). The
latter histological material was obtained by palliative surgery
due to local problems (transurethral resections of the prostate
(TUR-P)/transvesical prostatectomy (TV)), or represented a
diagnostic biopsy in order to differentiate between a growing
prostate cancer and rectal cancer (transrectal/transperineal
core biopsies). Patients displaying primary androgen-indepen-
dence, defined as clinical progression within 3 months after the
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ystart of castration therapy, were excluded from the present study.
Any concomitant or prior medical and/or surgical treatment was
allowed, whereas radiotherapy (RT) to the prostate prior to the
AIPC biopsy was a criterion for exclusion. In all, 10 specimens of
archival formalin-fixed normal prostate tissue represented a
clinical control group.
Clinical information
The following information was extracted from the medical records:
Initial diagnosis and treatment: Date, serum prostate-specific
antigen (PSA) level, extent of the disease categorised as local,
regional or distant metastases according to the registration
routines of the Cancer Registry of Norway (www.kreftregisteret.
no), date of start and type of androgen deprivation.
Clinical course and diagnosis of AIPC: Date and type of
clinical progression (local vs distant), date and status of last
observation (death or 15 October 2001). For all PRTR and AIPC
biopsies, we recorded the date and type of biopsy together with
the Gleason score, the latter differentiating between Gleason
score 7a (grade 3þ4) and Gleason score 7b (grade 4þ3) (Lilleby
et al, 2001).
Immunohistochemistry
For each eligible patient, the archival paraffin blocks of the PRTR
biopsy and of the first available biopsy after diagnosis of AIPC
were collected. Serial paraffin sections (5mm thick) were cut from
the blocks with the most representative amount of tumour tissue,
as determined in haematoxylin and eosin-stained slides. The newly
cut sections were mounted on silane-coated slides and dried for 1h
in 561C followed by 371C overnight. The sections were depar-
affinised, rehydrated and incubated with 0.3% H2O2 in methanol
for 30min to block endogenous peroxidase. The pretreatment
conditions and the primary antibodies against PSA and the EGFRs
are presented in Table 1. Automatic immunostaining with the
biotin–streptavidin amplified (B-SA) system (Optimax
s Auto-
mated Cell Staining System Plus, BioGenex, San Raman, CA, USA)
was applied. All series included both a positive control (known
positive case) and a negative control in which a nonreacting
immunoglobulin of the same subclass had substituted the primary
antibody. All controls were satisfactory.
Scoring procedure
The results of the immunostaining were reviewed by an
experienced pathologist (JMN) and scored semiquantitatively as
follows: no staining:  (minus); scattered cells to less than 1%
tumour cells positive: þ;1t oo10% tumour cells positive: þþ;
10–50% tumour cells positive: þþþand 450% cells positive:
þþþþ. Scores of  , þ and þþ were grouped together as
‘immunohistochemistry (IHC)-negative’ as opposed to ‘IHC-
positive’ findings in the examination of the clinical impact. For
the EGFRs, only moderate to strong cell membrane-specific
immunostaining was taken into account.
Statistics
Statistical analyses were performed using the computer-based
program SPSS (Statistical Package for Social Sciences) version 10.0.
Individual changes of immunostaining after diagnosis of AIPC
were assessed by the McNemar test for related samples. The overall
survival was estimated by the Kaplan–Meier method from the date
of the AIPC biopsy to the last observation/death applying the
logrank test to assess statistical significance. P-values o0.05 were
regarded statistically significant.
RESULTS
Patient characteristics
A total of 106 prostate cancer patients (diagnosed 1970–1997)
fulfilled the eligibility criteria. The median age at initial diagnosis
was 70 years (range: 50–86) (Table 2). In total, 23% of the patients
had distant metastases at the time of initial diagnosis. Only five of
34 patients with initially available serum PSA values displayed
levels less than 10mg/l. Androgen deprivation was started within
median 2 months after initial diagnosis (range 0–109). After a
median time of 32 months (range 7–167) AIPC was diagnosed in
all patients. Distant metastases were recorded for 43 patients after
the development of AIPC. Of the 105 PRTR biopsies evaluable for
Gleason score, 79% were X7b (Table 3). All AIPC biopsies were
Gleason score X7b.
Immunostaining
The percentage of PSA immunoreactive specimens decreased from
83% (88 of 106 patients) to 69% (73 patients) as the patients
developed AIPC (Table 3). A total of 21 patients lost PSA positivity
as they developed AIPC. Before androgen deprivation, c-erbB-1
positivity was demonstrated in 24 patients (23%) and in 46
patients (43%) after the development of AIPC (P¼0.001). The
comparable figures for c-erbB-2 were 33% and 24%, respectively.
Table 1 Primary antibodies and conditions
Antibody against Source Cat. no. Dilution Pretreatment
PSA DAKO, CA, USA M0750 1:20 Microwave 2 5min
a
c-erbB-1 DAKO, CA, USA M3563 1:100
b Pronase 10min
c-erbB-2 Novocastra Laboratories Ltd, Newcastle, UK NCL-CB11 1:200 Microwave 2 5min
c-erbB-3 SantaCruz Biotechnology Inc., CA, USA SC-415 1:50 None
c-erbB-4 SantaCruz Biotechnology Inc., CA, USA SC-283 1:50 Microwave 2 5min
aIn 10mmol/l citrate buffer (pH 6.0).
bApplied overnight.
Table 2 Demographics at diagnosis of prostate cancer
Age (years) 70 (50–86)
a
Extent of the disease
Loco-regional 81 (76%)
b
Distant metastases 24 (23%)
Unknown 1 (1%)
Primary hormone treatment
Orchiectomy 56 (53%)
LHRH analogues 33 (31%)
Combined LHRH analogues/antiandrogens 15 (14%)
Oestrogens 2 (2%)
Initial diagnosis to diagnosis of AIPC (months) 32 (7–167)
aMedian (range).
bNumber of patients (%).
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yc-erbB-1 and c-erbB-2 IHC positivity after the development of
AIPC is illustrated by Figure 1A–B.
The EGFRs remained negative in 48–71% of the patients during
the development of AIPC (Figure 2). Of 82 patients whose PRTR
biopsies were c-erbB-1-negative, 31 displayed c-erbB-1 positivity
in their AIPC biopsy (P¼0.001). However, nine of 24 patients with
c-erbB-1 positivity before hormone treatment lost this immunor-
eactivity after the development of AIPC. The direction of
intrapatient changes for c-erbB-2, c-erbB-3 and c-erbB-4 was less
pronounced. Overall, the positivity of EGFRs was not significantly
related to Gleason score or PSA immunoreactivity (data not
shown). During the development of AIPC, the number of c-erbB-1-
positive specimens was doubled in those patients who lost PSA
positivity, whereas the number of c-erbB-2 positive specimens
decreased from eight to three (Table 4). For the 10 specimens of
normal prostate tissue, four displayed c-erbB-1 positivity, whereas
none were positive for c-erbB-2, c-erbB-3 or c-erbB-4.
Survival
At the time of the last observation, 91 patients (86%) were dead.
The median overall survival time from the date of the AIPC biopsy
was 20 months (95% CI: 15–26 months). The immunoreactivity of
c-erbB-2 determined decreased survival (P¼0.029) (Figure 3A),
whereas the positivity of c-erbB-4 tended to indicate a better 2-year
survival than c-erbB-4 negativity (P¼0.054) (Figure 3B) (Table 5).
The coexpression of c-erbB-1 and c-erbB-2 in the AIPC biopsy (17
patients) did not represent a statistically significant poor prognosis
factor (P¼0.064).
DISCUSSION
In this descriptive study, 43% of the prostate cancer specimens
obtained from growing pelvic tumours of AIPC patients expressed
the c-erbB-1 protein and 24% expressed c-erbB-2, the latter being a
poor prognosis factor. During the development of AIPC,
intrapatient changes occurred in two opposite directions for each
of the four EGFRs: (1) negativity of the PRTR biopsies changed to
positivity of the paired AIPC biopsies and (2) positivity of the
PRTR biopsies changed to negativity of the paired AIPC biopsies.
The development of AIPC was significantly associated with the
increase of c-erbB-1 expression, whereas no changes for the other
growth factor receptors reached the level of statistical significance.
The Gleason score and PSA immunoreactivity were not associated
with growth factor receptor expression before or after the
development of AIPC. In normal prostate tissue, four out of 10
specimens displayed c-erbB-1 positivity, whereas none were
positive for c-erbB-2, c-erbB-3 or c-erbB-4.
Previous observations of the expression of c-erbB-1 and c-erbB-
2 in prostate cancer tissue and cell lines have demonstrated highly
divergent rates. Our results display figures far below the highest
reported values of c-erbB-1 and c-erbB-2 expression, but for c-
erbB-2 our figures are higher than the results from Savinainen et al
(2002). The following explanations are offered: Firstly, the cancer
cell population in biopsies from human AIPC is much more
heterogeneous than that from laboratory cell lines. Secondly, there
Table 3 Histological specimens
PRTR biopsy AIPC biopsy P
a
Type of biopsy
TUR-P 26 (25%) 99 (93%)
TV prostatectomy 7 (7%) —
Transrectal/transperineal core biopsy 73 (69%) 7 (7%)
Gleason score
p7a (grade 3+4) 21 (20%) —
X7b (grade 4+3) 84 (79%) 106 (100%)
Not evaluable 1 (1%) —
IHC positivity
PSA 88 (83%) 73 (69%) 0.006
c-erbB-1 24 (23%) 46 (43%) 0.001
c-erbB-2 35 (33%) 25 (24%) 0.174
c-erbB-3 15 (14%) 22 (21%) 0.21
c-erbB-4 25 (24%) 31 (29%) 0.43
aMcNemar test for related samples.
A
B
Figure 1 Immunohistochemical detection after the development of
AIPC of (A) c-erbB-1 (magnification  40) and (B) c-erbB-2 (magnification
 20).
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from the prostatic tumour, as used in the present study, and that
observed in metastatic cancer tissue as examined by Scher et al
(1995). Tissue from metastases may express higher levels of growth
factor receptors than the primary tumour. Thirdly, several
methodological differences as to IHC may lead to variability of
the results. In our study, only moderate or strong membrane
staining was considered a positive finding, whereas both Scher et al
(1995) and Di Lorenzo et al (2002) included weak membrane
staining of c-erbB-1 in their cohort of positive specimens. The use
of different antibodies represents another cause of variability of
the results. Finally, uncontrollable variations as the duration of
formalin fixation of the archival specimens may additionally
influence the immunoreactivity of EGFRs.
The results of the present study are in agreement with the
published observations: expression of c-erbB-1 increases signifi-
cantly, as the tumour becomes androgen independent. Xie et al
(1995) reported that c-erbB-1-mediated signals are associated with
the invasiveness of DU-145 human prostate carcinoma cells.
However, we were unable to confirm the findings of Di Lorenzo
et al (2002), that c-erbB-1 expression increased with increasing
Gleason score. Unlike the series of Di Lorenzo et al, 80% of the
untreated cases of the present study were already Gleason score
X7b. Di Lorenzo et al also found a positive correlation between
serum PSA and c-erbB-1, which was not confirmed in our study
applying IHC-detected PSA. Lee et al (2003) indicated that
decreased PSA secretion in androgen-independent LNCaP C-81
cells is associated with a low expression of c-erbB-2, similar to our
observation of a trend of reduced c-erbB-2 expression in biopsies
that became PSA negative.
Even though high levels of c-erbB-1 can be demonstrated in
human prostate cancer, especially after the development of AIPC,
its clinical role is not yet clear. This receptor’s function is further
obscured as it has become clear that internalisation has to take
place for its activation (Kim et al, 2003). Thus, the protein
expression of c-erbB-1 per se is only one of several conditions for
this receptor’s functionality.
The role of c-erbB-2 in prostate cancer is also controversial,
contrary to this receptor’s clinical importance for advanced breast
cancer (Cobleigh et al, 1999; Slamon et al, 2001). As seen in the
present study, immunoreactivity for this receptor has been
reported in 9% (Mark et al, 1999) up to 30% in untreated patients
(20%, Osman et al, 2001; 25%, Signoretti et al, 2000; 29%, Xie
et al, 1995; and 30%, Fossa et al, 2002). Savinainen et al (2002) did
not find c-erbB-2 immunoreactivity in any of 54 specimens from
untreated patients, nor in 20 lymph node metastases or 50
hormone-refractory tumours. The percentage of c-erbB-2-positive
cases among untreated prostate cancer patients thus seems
generally lower than in breast cancer. During the development of
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Table 4 Growth factor receptors in 21 patients with a PSA-positive
PRTR biopsy changing to PSA negativity at the development of AIPC
PRTR biopsy AIPC biopsy P
a
IHC positivity
c-erbB-1 6 (29%) 11 (52%) 0.180
c-erbB-2 8 (38%) 3 (14%) 0.125
c-erbB-3 5 (24%) 5 (24%) 1.00
c-erbB-4 7 (33%) 7 (33%) 1.00
aMcNemar test for related samples.
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Figure 3 (A) C-erbB-2 stainability of the AIPC biopsy and overall
survival. — c-erbB-2 negative (81), ----c-erbB-2 positive (25). (B)C -
erbB-4 stainability of the AIPC biopsy and overall survival. — c-erbB-4
negative (75), - - - - c-erbB-4 positive (31).
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(Xie et al, 1995; Signoretti et al, 2000; Osman et al, 2001), contrary
to our results that showed reversal to c-erbB-2 negativity in 27
out of 35 AIPC patients. The c-erbB-2 immunoreactivity may,
however, still be important in the clinical management of a
subgroup of these patients, and Moasser et al (2001) found that cell
lines expressing c-erbB-2 are particularly sensitive to ZD1839.
Furthermore, c-erbB-2 and c-erbB-3 frequently act together
creating heterodimers. Recently, a naturally occurring inhibitor
of c-erbB-3 has been detected (Lee et al, 2001), and at least in
some tumour cell lines, ZD1839 also inhibits c-erbB-3 (Moasser
et al, 2001).
Both c-erbB-1 and c-erbB-2 immunoreactivity have been shown
to be associated with an unfavourable prognosis in a homogenous
series of hormonally untreated cancer patients, in particular if
these two receptors are combined (Di Lorenzo et al, 2002). Owing
to the clinical heterogeneity of our untreated cases, we did not
perform a survival analysis based on the PRTR biopsies. However,
we found a significant association between c-erbB-2 positivity of
AIPC biopsies and a poor prognosis, whereas coexpression of
c-erbB-1 and c-erbB-2 in AIPC patients was not statistically
significantly associated with an unfavourable prognosis. The
finding of a slightly better survival in AIPC patients with c-erbB-
4 immunoreactivity needs further confirmation. Previously, the
association between c-erbB-4 positivity and a better clinical
outcome has been demonstrated for advanced breast cancer
patients (Suo and Nesland, 2002).
The strength of the present study is its large number of patients
and the possibility to analyse intrapatient changes of expression of
EGFRs during the development of AIPC. Our investigations of
EGFRs are, however, limited to IHC only. The correlation between
IHC-detected c-erbB-2 expression and comparable results of FISH
analyses has been debated (Press et al, 2002). Analysis by IHC
labels the gene product and has been sufficiently accurate for
screening purposes, defining positive cases by moderate or strong
membrane-specific staining in 410% of the tumour cells. On the
other hand, the FISH technique demonstrates gene amplification,
and is currently applied in breast cancer patients with nonconclu-
sive c-erbB-2 IHC results and possible therapeutic consequences. It
may be discussed whether the pattern of expression of EGFRs in
our AIPC patients, all with local problems, is representative for
AIPC patients in general. As we have previously indicated, the
clinical course and survival of AIPC patients with local problems
seem to differ from that of AIPC patients with symptomatic bone
metastases (Hernes et al, 2000; Hernes et al, 2003).
In summary, we find that during the development of AIPC
intrapatient changes occur in two opposite directions for each of
the four EGFRs: negativity change to positivity, and vice versa,
statistically significant only for the increase of c-erbB-1 expression
(P¼0.001). c-erbB-2 is a poor prognosis factor in AIPC patients
with local problems. These findings support ongoing attempts to
develop new treatment strategies for subgroups of prostate cancer
patients with the inhibition of EGFRs and their signalling
pathways. The sole immunohistochemical demonstration of
membrane-located EGFRs in biopsies may give some indications
for these agents’ efficacy in the individual patient. However, these
receptors’ final association with response rates has to be
determined in larger series of patients with known growth factor
receptor status.
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